MARKET

PTGX

PTGX

Protagonist Ther
NASDAQ
100.88
+2.51
+2.55%
After Hours: 100.88 0 0.00% 16:10 05/20 EDT
OPEN
99.03
PREV CLOSE
98.37
HIGH
101.90
LOW
98.37
VOLUME
371.68K
TURNOVER
--
52 WEEK HIGH
107.84
52 WEEK LOW
44.04
MARKET CAP
6.49B
P/E (TTM)
-55.9264
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PTGX last week (0511-0515)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL)
TipRanks · 6d ago
Protagonist Therapeutics director Bryan Giraudo disposes 59,130 shares worth $5.92 million
PUBT · 05/12 00:26
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Protagonist Therapeutics (PTGX)
TipRanks · 05/11 13:02
Weekly Report: what happened at PTGX last week (0504-0508)?
Weekly Report · 05/11 10:20
Protagonist Therapeutics price target raised to $130 from $125 at Citi
TipRanks · 05/10 14:07
Protagonist Therapeutics (PTGX) Receives a Buy from Citi
TipRanks · 05/10 13:37
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
TipRanks · 05/07 10:08
More
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).

Webull offers Protagonist Therapeutics Inc stock information, including NASDAQ: PTGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTGX stock methods without spending real money on the virtual paper trading platform.